Sinphar Pharmaceutical Co.,Ltd. (TPE:1734)
Taiwan · Delayed Price · Currency is TWD 32.10
0.00 (0.00%)
Sep 24, 2026, 1:30 PM CST
Sinphar Pharmaceutical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,451 | 3,371 | 3,151 | 2,963 | 2,857 | 2,434 | |
Revenue Growth | 7.08% | 7.00% | 6.33% | 3.72% | 17.39% | 1.89% |
Cost of Revenue | 1,912 | 1,912 | 1,910 | 1,869 | 1,764 | 1,545 |
Gross Profit | 1,538 | 1,459 | 1,240 | 1,094 | 1,093 | 888.71 |
Selling, General & Admin | 976.04 | 894.67 | 791.65 | 670.93 | 621.34 | 557.06 |
Research & Development | 151.68 | 145.37 | 151.36 | 132.58 | 272.16 | 511.88 |
Operating Expenses | 1,128 | 1,040 | 943.15 | 805.19 | 893.97 | 1,071 |
Operating Income | 410.47 | 419.39 | 297.16 | 288.74 | 198.63 | -182.77 |
Interest Expense | -33.86 | -33.85 | -36.77 | -33.71 | -27.81 | -24.8 |
Interest & Investment Income | 13.06 | 13.25 | 16.84 | 12.31 | 5.78 | 3.68 |
Currency Exchange Gain (Loss) | -3.76 | -19 | 13.43 | 3.79 | 21.31 | -6.96 |
Other Non Operating Income (Expenses) | 21.18 | 22.66 | 18.93 | 29.46 | 47.96 | 27.82 |
EBT Excluding Unusual Items | 407.1 | 402.46 | 309.58 | 300.58 | 245.86 | -183.03 |
Gain (Loss) on Sale of Investments | 0.1 | 0.12 | - | - | - | - |
Gain (Loss) on Sale of Assets | -0.84 | -1.05 | -2.48 | 5.13 | -0.81 | -1.5 |
Pretax Income | 406.36 | 401.52 | 307.1 | 305.71 | 245.05 | -184.53 |
Income Tax Expense | 68.04 | 47.25 | 21.88 | -51.07 | 80.87 | 20.43 |
Earnings From Continuing Operations | 338.32 | 354.27 | 285.22 | 356.78 | 164.17 | -204.96 |
Minority Interest in Earnings | 13.36 | 11.48 | 19.49 | 18.39 | 60.47 | 166.82 |
Net Income | 351.67 | 365.75 | 304.71 | 375.17 | 224.64 | -38.14 |
Net Income to Common | 351.67 | 365.75 | 304.71 | 375.17 | 224.64 | -38.14 |
Net Income Growth | 13.50% | 20.03% | -18.78% | 67.01% | - | - |
Shares Outstanding (Basic) | 202 | 202 | 202 | 202 | 202 | 202 |
Shares Outstanding (Diluted) | 202 | 202 | 202 | 202 | 202 | 202 |
Shares Change | 0.04% | 0.05% | 0.01% | -0.00% | 0.17% | - |
EPS (Basic) | 1.74 | 1.81 | 1.51 | 1.86 | 1.11 | -0.19 |
EPS (Diluted) | 1.74 | 1.81 | 1.51 | 1.86 | 1.11 | -0.19 |
EPS Growth | 13.16% | 20.00% | -18.84% | 66.91% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 331.81 | 389.95 | 353.08 | 0.86 | 283.82 | -10.64 |
Free Cash Flow Per Share | 1.64 | 1.93 | 1.75 | 0.00 | 1.41 | -0.05 |
Dividend Per Share | 0.943 | 0.943 | 0.898 | 0.832 | 0.832 | 0.166 |
Dividend Growth | 5.00% | 5.00% | 8.01% | 0% | 399.94% | 0% |
Gross Margin | 44.58% | 43.29% | 39.37% | 36.92% | 38.25% | 36.52% |
Operating Margin | 11.90% | 12.44% | 9.43% | 9.74% | 6.95% | -7.51% |
Profit Margin | 10.19% | 10.85% | 9.67% | 12.66% | 7.86% | -1.57% |
Free Cash Flow Margin | 9.62% | 11.57% | 11.21% | 0.03% | 9.93% | -0.44% |
EBITDA | 653.96 | 660.1 | 539.99 | 518.14 | 446.69 | 63.93 |
EBITDA Margin | 18.95% | 19.58% | 17.14% | 17.49% | 15.64% | 2.63% |
D&A For EBITDA | 243.49 | 240.71 | 242.83 | 229.4 | 248.06 | 246.7 |
EBIT | 410.47 | 419.39 | 297.16 | 288.74 | 198.63 | -182.77 |
EBIT Margin | 11.90% | 12.44% | 9.43% | 9.74% | 6.95% | -7.51% |
Effective Tax Rate | 16.74% | 11.77% | 7.13% | - | 33.00% | - |